Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is being conducted to improve standards of care in the cosmetic treatment of sun damage, fine lines, and wrinkles. VI Peels® and Botox® have been used cosmetically to improve patient concerns as monotherapies. This study seeks to confirm that the same-day combination creates no additional side-effects and furthermore that patient satisfaction is heightened as a result.
This study seeks to utilize the mechanisms of action of both products to simultaneously address fine lines and wrinkles. VI Peels contain a synergistic blend of acids that produce keratolytic and kerato-coagulation qualities focused on desquamation and cellular renewal. The VI Peel blend contains Trichloroacetic Acid, Phenol, Salicylic Acid, Retinoic Acid and Ascorbic Acid. Botox containing Botulinum toxin type A is a purified substance, derived from a bacterium that block muscular nerve signals temporarily preventing the muscular contraction and subsequent wrinkle formation.
The expected benefit of this investigational combination include improvements to Standards of Care in relation to treatment of the cosmetic patient by establishing safety of the combination treatment, improving patient outcomes by simultaneously addressing sun damage, fine lines, and wrinkles through dual mechanisms, and overall improvement to patient satisfaction.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | Experimental | Subjects will be given the same-day combination of VI Peel (Procedure) and Botox Cosmetic (Botulinum Toxin) (Drug). Botox will be administered via intramuscular injection via package insert to Glabella, Forehead and Crows Feet. Dosage will follow package insert guidelines. The two interventions will be administered once at the start of the study, subsequent study visits will focus on assessment and evaluation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug) | Combination Product | Same-Day combination of VI Peel applied to the full face, followed by Botox injection per label to the face. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Treatment-Emergent Adverse Events | To establish safety of the same-day combination of VI Peel & Botox, the study will measure the rate and occurrence of Adverse Events as compared to a stand-alone treatment of Botox. Rate and occurrence of Botox as a stand-alone intervention will be based off of the package insert indicating each Adverse Event | Day 7 (+/- 3) |
| Measure | Description | Time Frame |
|---|---|---|
| Change to Facial Wrinkle Severity | Overall improvements to fine lines and wrinkles will be measured using the Facial Wrinkle Severity Scale described below. Facial Wrinkle Severity Scale (FWSS) Grade 0 = no wrinkles; Grade 1 = mild wrinkles; Grade 2 = moderate wrinkles; and Grade 3 = severe wrinkles. Principal investigator will rate and measure subject on enrollment into the study, will grade again at Day 7 (+ / - 3) and again at Day 30. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Is pregnant or lactating
Has an active infection on their face (excluding acne)
Has used Isotretinoin (Accutane) within the last six months
Has had chemotherapy or radiation treatments within the last six months
Has a history of neuromuscular disorders
Has a history of bleeding disorders
Has an allergy to albumin
Has an allergy to Aspirin
Has an allergy to Phenol
Has received the following treatments in the last 6 months:
botulinum toxin, soft tissue filler, medium to deep chemical peel, ablative laser, radio frequency treatment, ultrasound device treatment, non-ablative laser treatment
Is planning on receiving in the next 1months: soft tissue filler, medium to deep chemical peel, ablative laser, radio frequency treatment, ultrasound device treatment, nonablative laser treatment
Is unable to understand the protocol or to give informed consent
Not willing to comply with all study requirements including return visits and photographs (eyes censored or uncensored)
Has been diagnosed or is displaying COVID-19 symptoms -
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wendy E Roberts, MD | Principal Investigator | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dr. Wendy E. Roberts, MD | Rancho Mirage | California | 92270 | United States |
Not provided
| Label | URL |
|---|---|
| MedlinePlus: Botox Cosmetic Overview | View source |
| U.S. FDA Resources | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001905 | Botulinum Toxins |
| D004364 | Pharmaceutical Preparations |
| D019274 | Botulinum Toxins, Type A |
| D014080 | Tooth Exfoliation |
| D009498 | Neurotoxins |
| D002615 | Chemexfoliation |
| ID | Term |
|---|---|
| D008666 | Metalloendopeptidases |
| D010450 | Endopeptidases |
| D010447 | Peptide Hydrolases |
| D006867 | Hydrolases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Baseline, 7 (+/- 3) Days after Intervention, and 30 Days after Intervention |
| Change to Uniformity of Pigment | Overall improvements to pigment will be measured using the Uniformity of Pigment Scale described below. Uniformity of Pigment; Grade 0 = Uniform, Grade 1 = mild, Grade 2 = moderate, Grade 3 = moderate to severe, Grade 4 = Severely Ununiform. Principal investigator will rate and measure subject on enrollment into the study, will grade again at Day 7 (+ / - 3) and again at Day 30. | Baseline, 7 (+/- 3) Days after Intervention, and 30 Days after Intervention |
| Change to | Overall improvements to Skin Tone will be measured via the Skin Tone grading scale below. Skin Tone; Grade 0 = Clear and Radiant, Grade 1 = Mild Irregularities, Grade 2 = Moderate Irregularities, Grade 3 = Moderate to Severe Irregularities, Grade 4 = Severe Irregularities, ie. Sallow, Dull. Principal investigator will rate and measure subject on enrollment into the study, will grade again at Day 7 (+ / - 3) and again at Day 30. | Baseline, 7 (+/- 3) Days after Intervention, and 30 Days after Intervention |
| D004798 |
| Enzymes |
| D045762 | Enzymes and Coenzymes |
| D045726 | Metalloproteases |
| D001426 | Bacterial Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D001427 | Bacterial Toxins |
| D014118 | Toxins, Biological |
| D001685 | Biological Factors |
| D009063 | Dental Physiological Phenomena |
| D055688 | Digestive System and Oral Physiological Phenomena |
| D009676 | Noxae |
| D004786 | Toxic Actions |
| D020164 | Chemical Actions and Uses |
| D003357 | Cosmetic Techniques |
| D013812 | Therapeutics |
| D062109 | Dermatologic Surgical Procedures |
| D019651 | Plastic Surgery Procedures |
| D013514 | Surgical Procedures, Operative |